These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 25252136

  • 1. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A, Saramäki OR, Zlobec I, Rotzer D, Genitsch V, Seiler R, Visakorpi T, Thalmann GN.
    Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
    [Abstract] [Full Text] [Related]

  • 2. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [Abstract] [Full Text] [Related]

  • 3. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C, Menan D, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Simon R, Schlomm T, Steurer S, Krech T.
    BMC Cancer; 2015 Jul 23; 15():538. PubMed ID: 26202067
    [Abstract] [Full Text] [Related]

  • 4. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.
    Prostate; 2013 Feb 15; 73(3):242-9. PubMed ID: 22821767
    [Abstract] [Full Text] [Related]

  • 5. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.
    Krstanoski Z, Vokac NK, Zagorac A, Pospihalj B, Munda M, Dzeroski S, Golouh R.
    BMC Urol; 2016 Jul 04; 16(1):35. PubMed ID: 27377958
    [Abstract] [Full Text] [Related]

  • 6. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
    Barros-Silva JD, Ribeiro FR, Rodrigues A, Cruz R, Martins AT, Jerónimo C, Henrique R, Teixeira MR.
    Genes Chromosomes Cancer; 2011 Aug 04; 50(8):662-71. PubMed ID: 21584900
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.
    Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL.
    Cancer Res; 2009 Feb 15; 69(4):1400-6. PubMed ID: 19190343
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L, Zhu XZ, Wang Y, Gong Y, Guo CC.
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun 15; 40(6):392-6. PubMed ID: 21914348
    [Abstract] [Full Text] [Related]

  • 11. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J.
    Cancer Res; 2006 Nov 15; 66(22):10658-63. PubMed ID: 17108102
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, Jung K, Stephan C, Kristiansen G.
    Int J Cancer; 2013 Feb 15; 132(4):807-12. PubMed ID: 22821757
    [Abstract] [Full Text] [Related]

  • 14. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M.
    Prostate; 2011 Apr 15; 71(5):489-97. PubMed ID: 20878952
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ERG rearrangement is present in a subset of transition zone prostatic tumors.
    Falzarano SM, Navas M, Simmerman K, Klein EA, Rubin MA, Zhou M, Magi-Galluzzi C.
    Mod Pathol; 2010 Nov 15; 23(11):1499-506. PubMed ID: 20693982
    [Abstract] [Full Text] [Related]

  • 17. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
    Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG.
    Clin Cancer Res; 2013 Sep 15; 19(18):5202-9. PubMed ID: 23918607
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA.
    J Urol; 2010 May 15; 183(5):2054-61. PubMed ID: 20303538
    [Abstract] [Full Text] [Related]

  • 20. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
    Kiflemariam S, Mignardi M, Ali MA, Bergh A, Nilsson M, Sjöblom T.
    J Pathol; 2014 Oct 15; 234(2):253-61. PubMed ID: 24931216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.